Hi Koo,

I wasn't interested in the letter-to-the-editor itself since it didn't contain any new information.  I just posted it to show the context for the response to the letter that was written by the authors of the original multicenter PAH work. They said:

"To date, the total exposure in patients with high-risk CV disease is approaching 2,000 subjects, with no heart failure signal identified. To ensure the safety of the drug in the context of right ventricular dysfunction, we conducted experiments in a rat model of increased ventricular afterload induced by pulmonary artery banding. Treatment with RVX208 was not accompanied by deleterious effects, and, on the contrary, promoted the ventricular response to increased afterload (1)."

This seems to me to possibly relate to the positive effect on Congestive Heart Failure that apabetaone had in the BoM trial.  I know nothing about CHF and am hoping that one of our doctors can expand on the topic a bit.  BTW, I note the following under the BoM exclusion criteria; again, not clear on what it means.

"Previous/current diagnosis of severe heart failure or documented LVEF<25% determined by contrast left ventriculography, radionuclide ventriculography or echocardiography. Absence of LVEF measurement in subject w/out a previous/current diagnosis of heart failure does not exclude entry into study"

Jupe